A pangenotypic, single tablet regimen of sofosbuvir/velpatasvir for the treatment of chronic hepatitis C infection.

about

Sofosbuvir, velpatasvir and voxilaprevir combination for the treatment of hepatitis C.Real-world cure rates for hepatitis C virus treatments that include simeprevir and/or sofosbuvir are comparable to clinical trial results.Hepatitis virus (HCV) diagnosis and access to treatment in a UK cohort

P2860

Q39411801-80957387-00C0-44C0-8DAB-48F85F17EBAE Q45324716-512F10CE-3554-4F92-9325-8DCFA0B165FC Q56669606-CEC66BB7-F1C6-4BE0-84C4-0BBD140485B4

P2860

A pangenotypic, single tablet regimen of sofosbuvir/velpatasvir for the treatment of chronic hepatitis C infection.

Item

http://www.wikidata.org/entity/Q39090420

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

A pangenotypic, single tablet ...... chronic hepatitis C infection.

@en

A pangenotypic, single tablet ...... chronic hepatitis C infection.

@nl

type

Item

label

A pangenotypic, single tablet ...... chronic hepatitis C infection.

@en

A pangenotypic, single tablet ...... chronic hepatitis C infection.

@nl

prefLabel

A pangenotypic, single tablet ...... chronic hepatitis C infection.

@en

A pangenotypic, single tablet ...... chronic hepatitis C infection.

@nl

P1476

A pangenotypic, single tablet ...... chronic hepatitis C infection.

@en

P2093

Ilan S Weisberg

http://www.w3.org/2001/XMLSchema#string

Ira M Jacobson

http://www.w3.org/2001/XMLSchema#string

P2860

Global epidemiology and genotype distribution of the hepatitis C virus infection

Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of the Hepatitis C Virus NS5B Polymerase Inhibitor Sofosbuvir.

All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study.

Increasing prevalence of cirrhosis among U.S. adults aware or unaware of their chronic hepatitis C virus infection.

Antiviral activity and resistance of HCV NS5A replication complex inhibitors.

Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection.

Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection.

Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis.

Sofosbuvir Plus Velpatasvir Combination Therapy for Treatment-Experienced Patients With Genotype 1 or 3 Hepatitis C Virus Infection: A Randomized Trial.

Sofosbuvir With Velpatasvir in Treatment-Naive Noncirrhotic Patients With Genotype 1 to 6 Hepatitis C Virus Infection: A Randomized Trial.

P304

535-543

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/14656566.2017.1282459

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-01-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28092171

http://www.w3.org/2001/XMLSchema#string

P921

sofosbuvir

A pangenotypic, single tablet regimen of sofosbuvir/velpatasvir for the treatment of chronic hepatitis C infection.

about

P2860

P2860

A pangenotypic, single tablet regimen of sofosbuvir/velpatasvir for the treatment of chronic hepatitis C infection.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921